{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:00:33Z","timestamp":1782208833928,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10238-018-0540-3","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T05:12:24Z","timestamp":1543468344000},"page":"149-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer"],"prefix":"10.1007","volume":"19","author":[{"given":"Xifeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-0515","authenticated-orcid":false,"given":"Song","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changku","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"540_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"540_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10\u201329.","journal-title":"CA Cancer J Clin"},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.297.3.267","volume":"297","author":"H Oettle","year":"2007","unstructured":"Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267\u201377.","journal-title":"JAMA"},{"key":"540_CR4","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.2007.15.8634","volume":"26","author":"DB Evans","year":"2008","unstructured":"Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496\u2013502.","journal-title":"J Clin Oncol"},{"key":"540_CR5","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1245\/s10434-014-4192-6","volume":"22","author":"CL Roland","year":"2015","unstructured":"Roland CL, Yang AD, Katz MH, Chatterjee D, Wang H, et al. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:1168\u201375.","journal-title":"Ann Surg Oncol"},{"key":"540_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977\u201388.","journal-title":"Surgery"},{"key":"540_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3748\/wjg.v22.i2.776","volume":"22","author":"T Matsuoka","year":"2016","unstructured":"Matsuoka T, Yashiro M. Molecular targets for the treatment of pancreatic cancer: clinical and experimental studies. World J Gastroenterol. 2016;22:776\u201389.","journal-title":"World J Gastroenterol"},{"key":"540_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"540_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"540_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","volume":"17","author":"M Suker","year":"2016","unstructured":"Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801\u201310.","journal-title":"Lancet Oncol"},{"key":"540_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/oxfordjournals.epirev.a036298","volume":"9","author":"S Greenland","year":"1987","unstructured":"Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1\u201330.","journal-title":"Epidemiol Rev"},{"key":"540_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"540_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"540_CR14","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088\u2013101.","journal-title":"Biometrics"},{"key":"540_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/1471-2407-12-199","volume":"12","author":"PJ Hosein","year":"2012","unstructured":"Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.","journal-title":"BMC Cancer"},{"key":"540_CR16","first-page":"497","volume":"13","author":"PF Peddi","year":"2012","unstructured":"Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Jop. 2012;13:497\u2013501.","journal-title":"Jop"},{"key":"540_CR17","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/MPA.0b013e31829e2006","volume":"42","author":"H Mahaseth","year":"2013","unstructured":"Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311\u20135.","journal-title":"Pancreas"},{"key":"540_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jso.23392","volume":"108","author":"BA Boone","year":"2013","unstructured":"Boone BA, Steve J, Krasinskas AM, Zureikat AH, Lembersky BC, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236\u201341.","journal-title":"J Surg Oncol"},{"key":"540_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","volume":"18","author":"JE Faris","year":"2013","unstructured":"Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543\u20138.","journal-title":"Oncologist"},{"key":"540_CR20","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3109\/0284186X.2013.771821","volume":"52","author":"C Tinchon","year":"2013","unstructured":"Tinchon C, Hubmann E, Pichler A, Keil F, Pichler M, et al. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol. 2013;52:1231\u20133.","journal-title":"Acta Oncol"},{"key":"540_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s12032-012-0361-2","volume":"30","author":"KS Gunturu","year":"2013","unstructured":"Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30:361.","journal-title":"Med Oncol"},{"key":"540_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clcc.2014.09.005","volume":"13","author":"SY Moorcraft","year":"2014","unstructured":"Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer. 2014;13:232\u20138.","journal-title":"Clin Colorectal Cancer"},{"key":"540_CR23","doi-asserted-by":"publisher","first-page":"e198","DOI":"10.1097\/MD.0000000000000198","volume":"93","author":"A Paniccia","year":"2014","unstructured":"Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, et al. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014;93:e198.","journal-title":"Medicine (Baltimore)"},{"key":"540_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1634\/theoncologist.2013-0273","volume":"19","author":"KK Christians","year":"2014","unstructured":"Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266\u201374.","journal-title":"Oncologist"},{"key":"540_CR25","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.pan.2015.08.010","volume":"15","author":"M Khushman","year":"2015","unstructured":"Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-Bonilla A, Velez M, et al. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015;15:667\u201373.","journal-title":"Pancreatology"},{"key":"540_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","volume":"22","author":"L Marthey","year":"2015","unstructured":"Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295\u2013301.","journal-title":"Ann Surg Oncol"},{"key":"540_CR27","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1245\/s10434-015-4647-4","volume":"22","author":"E Sadot","year":"2015","unstructured":"Sadot E, Doussot A, O\u2019Reilly EM, Lowery MA, Goodman KA, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:3512\u201321.","journal-title":"Ann Surg Oncol"},{"key":"540_CR28","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","volume":"22","author":"M Blazer","year":"2015","unstructured":"Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153\u20139.","journal-title":"Ann Surg Oncol"},{"key":"540_CR29","first-page":"270","volume":"54","author":"X Bai","year":"2016","unstructured":"Bai X, Su R, Ma T, Shen S, Li G, et al. Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China. Zhonghua Wai Ke Za Zhi. 2016;54:270\u20135.","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"540_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/bjc.2016.45","volume":"114","author":"SM Stein","year":"2016","unstructured":"Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114:809\u201312.","journal-title":"Br J Cancer"},{"key":"540_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","volume":"264","author":"T Hackert","year":"2016","unstructured":"Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, et al. Locally Advanced Pancreatic Cancer: neoadjuvant therapy with FOLFIRINOX results in resectability in 60% of the patients. Ann Surg. 2016;264:457\u201363.","journal-title":"Ann Surg"},{"key":"540_CR32","doi-asserted-by":"publisher","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","volume":"151","author":"MH Katz","year":"2016","unstructured":"Katz MH, Shi Q, Ahmad SA, Herman JM, Marsh Rde W, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151:e161137.","journal-title":"JAMA Surg"},{"key":"540_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00280-016-3121-8","volume":"78","author":"KI Okada","year":"2016","unstructured":"Okada KI, Kawai M, Hirono S, Satoi S, Yanagimoto H, et al. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol. 2016;78:719\u201326.","journal-title":"Cancer Chemother Pharmacol"},{"key":"540_CR34","unstructured":"Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2017."},{"key":"540_CR35","doi-asserted-by":"crossref","first-page":"46337","DOI":"10.18632\/oncotarget.17940","volume":"8","author":"C Yoo","year":"2017","unstructured":"Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget. 2017;8:46337\u201347.","journal-title":"Oncotarget"},{"key":"540_CR36","first-page":"75","volume":"19","author":"BC Chapman","year":"2018","unstructured":"Chapman BC, Gleisner A, Rigg D, Messersmith W, Paniccia A, et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma. Jop. 2018;19:75\u201385.","journal-title":"Jop"},{"key":"540_CR37","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","volume":"4","author":"JE Murphy","year":"2018","unstructured":"Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:963\u20139.","journal-title":"JAMA Oncol"},{"key":"540_CR38","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cncr.22852","volume":"110","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer. 2007;110:738\u201344.","journal-title":"Cancer"},{"key":"540_CR39","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"B Chauffert","year":"2008","unstructured":"Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, et al. Phase III trial comparing intensive induction chemoradiotherapy (60\u00a0Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000\u20132001 FFCD\/SFRO study. Ann Oncol. 2008;19:1592\u20139.","journal-title":"Ann Oncol"},{"key":"540_CR40","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.","journal-title":"PLoS Med"},{"key":"540_CR41","first-page":"CD010244","volume":"2","author":"KS Gurusamy","year":"2014","unstructured":"Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014;2:CD010244.","journal-title":"Cochrane Database Syst Rev"},{"key":"540_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.surg.2011.07.006","volume":"150","author":"MM Assifi","year":"2011","unstructured":"Assifi MM, Lu X, Eibl G, Reber HA, Li G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466\u201373.","journal-title":"Surgery"},{"key":"540_CR43","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1200\/JCO.2005.06.023","volume":"23","author":"C Louvet","year":"2005","unstructured":"Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509\u201316.","journal-title":"J Clin Oncol"},{"key":"540_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2015.12.026","volume":"57","author":"T Conroy","year":"2016","unstructured":"Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016;57:10\u201322.","journal-title":"Eur J Cancer"},{"key":"540_CR45","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","volume":"27","author":"CA Iacobuzio-Donahue","year":"2009","unstructured":"Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806\u201313.","journal-title":"J Clin Oncol"},{"key":"540_CR46","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2014.59.7930","volume":"33","author":"GM Heestand","year":"2015","unstructured":"Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015;33:1770\u20138.","journal-title":"J Clin Oncol"},{"key":"540_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","volume":"44","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015;44:515\u201321.","journal-title":"Pancreas"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-018-0540-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-018-0540-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-018-0540-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T07:34:06Z","timestamp":1605512046000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-018-0540-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s10238-018-0540-3","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"assertion":[{"value":"21 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}